4-(乙基硫代)苯硼酸 | 145349-76-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-(乙基硫代)苯硼酸
• 中文别名: 4-乙巯基苯硼酸；4-乙硫基苯硼酸；4-乙基噻吩基硼酸
• 英文名称: 4-(ethylthio)phenylboronic acid
• 英文别名: 4-Ethylthiophenylboronic acid；(4-ethylsulfanylphenyl)boronic acid
• CAS: 145349-76-4
• 化学式: C₈H₁₁BO₂S
• mdl: MFCD01318146
• 分子量: 182.051
• InChiKey: LMUASBOUSAMURX-UHFFFAOYSA-N

物化性质

• 熔点：
  104-106°C
• 沸点：
  343.5±44.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.8
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  F,Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保存方法：密封于阴凉、通风干燥的地方。

SDS

Name:	4-(Ethylthio)Benzeneboronic Acid Material Safety Data Sheet
Synonym:	None Known
CAS:	145349-76-4

Section 1 - Chemical Product MSDS Name:4-(Ethylthio)Benzeneboronic Acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
145349-76-4	4-(Ethylthio)Benzeneboronic Acid	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 145349-76-4: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 104 - 106 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H11BO2S
Molecular Weight: 182.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents, acids, strong bases.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, boron oxides.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 145349-76-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Ethylthio)Benzeneboronic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 145349-76-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 145349-76-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 145349-76-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(乙基硫代)苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 哌啶 、 吡啶 、 氯化亚砜 、 potassium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  非硫醇法呢基转移酶抑制剂：N-（4-甲苯基乙酰氨基-3-苯甲酰基苯基）-3-芳基呋喃基丙烯酸酰胺。

  摘要：

  我们已经设计了芳基呋喃基丙烯酸取代的二苯甲酮作为非硫醇法呢基转移酶抑制剂，利用了法呢基转移酶的新型芳基结合位点。这些化合物在低纳摩尔范围内显示活性。

  DOI：

  10.1016/j.bmc.2004.07.010
• 作为产物：
  描述：

  1-溴-4-(乙基硫代)苯 在 正丁基锂 、 硼酸三甲酯 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以66%的产率得到4-(乙基硫代)苯硼酸
  参考文献：
  名称：

  功能性芳族多磺酰氯及其掩蔽前体的合成。

  摘要：

  含有苯乙酮和两个磺酰氯基团的功能性芳族双（磺酰氯）的合成，即3,5-双[4-（氯磺酰基）苯基] -1-乙酰苯（16），3,5-双（氯磺酰基） -1-苯乙酮（17）和3,5-双（4-（氯磺酰基）苯氧基）-1-苯乙酮（18）通过一系列反应进行，最后一步涉及S-（芳基）的定量氧化氯化-描述了N，N′-二乙基硫代氨基甲酸酯，烷基-或苄基硫代苯基作为磺酰氯的掩蔽的非反应性前体。相关的反应顺序用于合成芳族三磺酰氯1,1,1-三（4-氯磺酰苯基）乙烷（24）。4-（氯磺酰基）苯氧基乙酸，2,2-双[[[[（4-（氯磺酰基）苯氧基乙酰基]氧基]甲基] -1,3-丙二酸酯（27），5,11,17,23-四（氯磺酰基） -25,26,27，28-四（乙氧羰基甲氧基）杯[4]芳烃（38），5,11,17,23,29,35-六（氯磺酰基）-37,38,39,40,41,42-六（乙氧羰基甲氧基）杯[ 6]芳烃（39），5

  DOI：

  10.1021/jo001694x

文献信息

• [EN] INHIBITORS OF HUMAN ATGL<br/>[FR] INHIBITEURS DE L'ATGL HUMAIN
  申请人：KARL FRANZENS UNIV GRAZ

  公开号：WO2021019051A1

  公开（公告）日：2021-02-04

  The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

  本发明涉及新型抑制脂肪甘油三酯脂肪酶（ATGL）的抑制剂，其对人类ATGL（hATGL）具有改善的抑制活性，以及包含这些抑制剂的药物组合物，及其治疗用途，特别是在治疗或预防脂质代谢紊乱方面的用途，包括例如肥胖、非酒精性脂肪肝病、2型糖尿病、胰岛素抵抗、葡萄糖不耐症、高甘油三酯血症、代谢综合征、心脏和骨骼肌脂肪变性、先天性全身性脂肪营养不良、家族性部分脂肪营养不良、获得性脂肪营养不良综合征、动脉粥样硬化或心力衰竭。
• Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors
  作者：Romeo Romagnoli、Paola Oliva、Maria Kimatrai Salvador、Maria Encarnacion Camacho、Chiara Padroni、Andrea Brancale、Salvatore Ferla、Ernest Hamel、Roberto Ronca、Elisabetta Grillo、Roberta Bortolozzi、Fatlum Rruga、Elena Mariotto、Giampietro Viola

  DOI：10.1016/j.ejmech.2019.111577

  日期：2019.11

  derivatives, prepared as cis-rigidified combretastatin A-4 (CA-4) analogues, were synthesized and evaluated for their in vitro antiproliferative against six different cancer cell lines and, for selected highly active compounds, inhibitory effects on tubulin polymerization, cell cycle effects and in vivo potency. We retained the 3′,4′,5′-trimethoxyphenyl moiety as ring A throughout the present investigation

  一系列3-（3'，4'，5'-三甲氧基苯基）-4-取代的1 H-吡唑及其相关的3-芳基-4-（3'，4'，5'-三甲氧基苯基）-1- H合成了作为顺式刚性康普他汀A-4（CA-4）类似物制备的对吡唑区域异构衍生物，并评估了其对六种不同癌细胞系的体外抗增殖作用，并针对某些高活性化合物对微管蛋白聚合的抑制作用进行了评估，细胞周期效应和体内效力。在整个本研究中，我们保留了3'，4'，5'-三甲氧基苯基部分作为环A，并通过添加吸电子（OCF 3，CF 3）或第二个芳基环上的电子释放基团（烷基和烷氧基），对应于CA-4的B环，位于吡唑核的3或4位。另外，B环被苯并[ b ]噻吩-2-基部分取代。对于许多化合物，它们的活性均大于或与CA-4相当。在两种区域异构衍生物中观察到最大活性，其特征在于在1 H的C-3和C-4位置存在4-乙氧基苯基和3'，4'，5'-三甲氧基苯基，反之亦然-吡唑环。数据表明，3
• Nickel-Catalyzed Carbonylation of Difluoroalkyl Bromides with Arylboronic Acids
  作者：Hai-Yang Zhao、Xing Gao、Shu Zhang、Xingang Zhang

  DOI：10.1021/acs.orglett.8b04070

  日期：2019.2.15

  difluoroalkylation reaction with arylboronic acids under 1 atm of CO has been developed. The reaction proceeds under mild reaction conditions with high efficiency and high functional group tolerance. Preliminary mechanistic studies reveal that the arylacyl nickel complex is the key intermediate to circumvent the formation of labile fluoroacyl nickel, and bimetallic oxidative addition is likely the key

  已经开发了在1 atm CO的条件下与芳基硼酸进行镍催化的羰基化二氟烷基化反应。反应在温和的反应条件下以高效率和高官能团耐受性进行。初步的机理研究表明，芳基镍配合物是规避不稳定的氟代酰基镍形成的关键中间体，双金属氧化加成可能是促进催化循环的关键步骤。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004089885A1

  公开（公告）日：2004-10-21

  The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  这项发明涉及取代苯氧乙酸(I)作为治疗呼吸系统疾病的有用药物化合物，包含它们的药物组合物，以及它们的制备方法。
• Highly γ‐Selective Arylation and Carbonylative Arylation of 3‐Bromo‐3,3‐difluoropropene via Nickel Catalysis
  作者：Ran Cheng、Yueqian Sang、Xing Gao、Shu Zhang、Xiao‐Song Xue、Xingang Zhang

  DOI：10.1002/anie.202015921

  日期：2021.5.25

  mechanistic studies and density functional theory calculations reveal that both non‐radical and radical pathways are possible for the reaction, and the radical pathway is more likely. The high γ‐regioselectivity results from the β‐bromide elimination of alkylnickel(II) species or from the reductive elimination of nickel(III) species [(aryl)(CF2=CHCH2)NiIII(Ln)X]. The γ‐selective carbonylation of 3‐bromo‐3,3‐difluoropropene

  已经开发了镍催化的3-溴-3,3-二氟丙烯的高γ-区域选择性芳基化和羰基芳基化。该反应在温和的反应条件下进行，从而提供了高效率和良好的官能团耐受性的gem-二氟烯烃。所得的宝石二氟烯烃可作为多样化合成的多功能构建基块。初步的机理研究和密度泛函理论计算表明，非自由基和自由基途径均可用于该反应，而自由基途径则更有可能。高的γ-区域选择性是由于烷基溴（II）物种的β-溴消除或镍（III）物种[（芳基）（CF 2 = CHCH 2）Ni III（L n）X]。1 atm CO气体下3-溴3,3-二氟丙烯的γ选择性羰基化也为镍催化的羰基化提供了新途径。